Title: An Integrated Phase 2/3 and Phase 3 Trial of MRD-based Optimization of Adjuvant Therapy in Urothelial Can (Modern)
- Principal Investigator: Dr. Eric Knoche
- Co-Investigator: Erik Shannon
Muscle-invasive urothelial cancer of the bladder is associated with a high risk of metastatic recurrence despite curative intent surgery. The purpose of this study is to see if adjuvant PD-1 blockade with nivolumab improves disease-free survival in patients with muscle-invasive urothelial cancer at high risk for recurrence.
This project is a joint study with the St. Louis VA and The Washington University in St. Louis.
This study is administered by VREF and funded by the NCI (National Center Institute).
Find Out More
This project is currently enrolling patients. To learn more about MODERN and how you can join contact our research office at (314) 289-7690.
If you are a veteran receiving care through the VA St. Louis Health Care System and believe you may be eligible for this study, please speak with your Physician. For general information about our research, please visit our main Clinical Trials page or contact us directly.